MDS Nordion to Expand Facility to Meet Growing Demand for Medical Imaging Agent in Europe

MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals for molecular imaging, is investing U.S. $5.8 million / (euro) 4.5 million to expand its production facility in Fleurus, Belgium to meet the growing demand for a medical imaging agent used in cancer diagnosis and treatment. The agent, Fluorine-18 Fludeoxyglucose or FDG, is marketed and distributed by MDS Nordion under the name Glucotrace(R). Glucotrace(R) is used in a highly sensitive medical imaging technique called PET or Positron Emission Tomography. As cancer rates continue to rise in Europe, the use of PET is increasing to diagnose cancer and monitor patient progress while in treatment.

...

Want to see the full article?

• Purchase this article for only $3.00